Cargando…

GABARAPL1 Promotes AR+ Prostate Cancer Growth by Increasing FL-AR/AR-V Transcription Activity and Nuclear Translocation

The next generation Androgen receptor (AR)-targeted therapies are now in widespread clinical use and prolong prostate cancer (CaP) patient survival. However, the therapies are not curative due to diverse range of resistance mechanisms. AR variants (AR-V), one major mechanism of resistance, has recen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Bing, Zhang, Lijuan, Liu, Shenglin, Chen, Xiaofan, Zhang, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872515/ https://www.ncbi.nlm.nih.gov/pubmed/31803623 http://dx.doi.org/10.3389/fonc.2019.01254

Ejemplares similares

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
por: Wüstmann, Neele, et al.
Publicado: (2023)

Huaier Extract Inhibits Prostate Cancer Growth via Targeting AR/AR-V7 Pathway
por: Liu, Zhengfang, et al.
Publicado: (2021)

Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2
por: Labaf, Maryam, et al.
Publicado: (2022)

Ligand induced dissociation of the AR homodimer precedes AR monomer translocation to the nucleus
por: Shizu, Ryota, et al.
Publicado: (2019)

$^{43}$Ar and $^{44}$Ar
por: Hudis, J, et al.
Publicado: (1970)

$^{43}Ar$ and $^{44}Ar$
por: Hudis, J, et al.
Publicado: (1970)

To Be(Ar) Or Not to Be(Ar) – Jones Dilemma?
por: Andrews, Nicholas A., et al.
Publicado: (2022)

Non-nuclear AR Signaling in Prostate Cancer
por: Zamagni, Alice, et al.
Publicado: (2019)

Somatic Alterations Impact AR Transcriptional Activity and Efficacy of AR-Targeting Therapies in Prostate Cancer
por: Chauhan, Gaurav, et al.
Publicado: (2021)

Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer
por: Narayanan, Ramesh
Publicado: (2020)

Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer
por: Sugiura, Masahiro, et al.
Publicado: (2020)

On atmospheric $^{39}Ar$ and $^{42}Ar$ abundance
por: Cennini, P, et al.
Publicado: (1995)

Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer
por: Khan, Farhan, et al.
Publicado: (2023)

Ár njöt'i ar hai = El color de la tierra
Publicado: (2014)

The mass of $^{32}Ar$ and $^{33}Ar$ for fundamental tests
por: Blaum, K, et al.
Publicado: (2003)

Masses of 32Ar and 33Ar for fundamental tests
por: Blaum, K, et al.
Publicado: (2003)

AR Splicing Variants and Resistance to AR Targeting Agents
por: Kanayama, Mayuko, et al.
Publicado: (2021)

Boutique neutrons advance (40)Ar/(39)Ar geochronology
por: Rutte, Daniel, et al.
Publicado: (2019)

Baicalein suppresses the androgen receptor (AR)-mediated prostate cancer progression via inhibiting the AR N-C dimerization and AR-coactivators interaction
por: Xu, Defeng, et al.
Publicado: (2017)

Determination of $^{44}Ar$(n,$\gamma$)$^{45}$Ar, and $^{46}$Ar(n,$\gamma$)$^{47}$Ar reaction rates by (d,p) transfer reactions
por: Sorlin, O, et al.
Publicado: (2002)

ARS Leptogenesis
por: Drewes, M., et al.
Publicado: (2017)

Ars melancholiae
por: Weiss, Silvius Leopold, 1686-1750
Publicado: (1994)

Ars Obstetrica
por: Armytage, V. B. Green
Publicado: (1930)

Ars Gynæcologica
por: Green-Armytage, V. B.
Publicado: (1930)

Ars Obstetrica
por: Umachigi, V. S.
Publicado: (1930)

Ars Longa
Publicado: (1893)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
por: White, Ralph E., et al.
Publicado: (2023)

Development and feasibility evaluation of an AR-assisted radiotherapy positioning system
por: Zhang, Gongsen, et al.
Publicado: (2022)

AR, the cell cycle, and prostate cancer
por: Balk, Steven P., et al.
Publicado: (2008)

Androgen Receptor-Mediated Growth Suppression of HPr-1AR and PC3-Lenti-AR Prostate Epithelial Cells
por: Kim, Young-Chae, et al.
Publicado: (2015)

Molecular Phenotyping of AR Signaling for Predicting Targeted Therapy in Castration Resistant Prostate Cancer
por: Hamid, Agus Rizal A. H., et al.
Publicado: (2021)

Inhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated AR(ser81)
por: Mehraein-Ghomi, Farideh, et al.
Publicado: (2015)

AR mRNA stability is increased with AR-antagonist resistance via 3′UTR variants
por: Dart, D A, et al.
Publicado: (2019)

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

ACK1–AR and AR–HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers
por: Kim, Eric H, et al.
Publicado: (2020)

Diverse roles of androgen receptor (AR) domains in AR-mediated signaling
por: Claessens, Frank, et al.
Publicado: (2008)

Regulation of AR mRNA translation in response to acute AR pathway inhibition
por: Somasekharan, Syam Prakash, et al.
Publicado: (2021)

TMEM158 expression is negatively regulated by AR signaling and associated with favorite survival outcomes in prostate cancers
por: Huang, Jian, et al.
Publicado: (2022)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Ars medica mexicana
por: Pérez-Tamayo, Ruy

Cannot write session to /tmp/vufind_sessions/sess_mo3btg35sqbchjkp7p0nof66va